299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

11 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03375047 (ClinicalTrials.gov)	May 10, 2018	7/9/2017	Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis	A Phase 1/2, Randomized, Double-Blinded, Placebo-Controlled, Combined Single and Multiple Ascending Dose Study Evaluating the Safety, Tolerability, and Biological Activity of MRT5005 Administered by Nebulization to Adult Subjects With Cystic Fibrosis	Cystic Fibrosis	Drug: MRT5005;Drug: Normal saline	Translate Bio, Inc.	NULL	Recruiting	18 Years	N/A	All	40	Phase 1/Phase 2	United States
2	NCT02354859 (ClinicalTrials.gov)	March 2016	30/7/2014	A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)	A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)	Cystic Fibrosis	Drug: Gallium nitrate;Drug: Normal Saline	University of Washington	Cystic Fibrosis Foundation	Completed	18 Years	N/A	All	119	Phase 2	United States
3	NCT02081963 (ClinicalTrials.gov)	March 2014	6/3/2014	Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis	A Randomized, Controlled Study of Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis	Non-Cystic Fibrosis Bronchiectasis	Drug: Amikacin;Drug: Normal saline	Qilu Hospital of Shandong University	NULL	Completed	18 Years	80 Years	All	178	Phase 4	China
4	NCT01746784 (ClinicalTrials.gov)	February 2014	6/12/2012	Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation	A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of N6022 to Evaluate Safety and Pharmacokinetics in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation (SNO1)	Cystic Fibrosis	Drug: N6022;Drug: Normal saline	Nivalis Therapeutics, Inc.	NULL	Completed	18 Years	N/A	All	66	Phase 1	United States
5	NCT00996424 (ClinicalTrials.gov)	January 2010	15/10/2009	The Effect of Inhaled N-Acetylcysteine Compared to Normal Saline on Sputum Rheology and Lung Function	The Effect of Inhaled N-Acetylcysteine Compared to Normal Saline on Sputum Rheology and Lung Function.	Cystic Fibrosis	Drug: Acetylcysteine;Drug: normal saline	University Hospital, Ghent	BVSM	Terminated	6 Years	64 Years	Both	19	Phase 4	Belgium
6	EUCTR2008-008317-20-BE (EUCTR)	13/11/2009	21/09/2009	The effect of inhaled N-Acetylcysteine compared to normal saline on sputum rheology and lung function	The effect of inhaled N-Acetylcysteine compared to normal saline on sputum rheology and lung function	Cystic Fibrosis MedDRA version: 12.0;Level: LLT;Classification code 10011762;Term: Cystic fibrosis	Trade Name: Lysomucil 10 % Product Name: N-acetylcysteine INN or Proposed INN: Acetylcysteine	University Hospital Ghent	NULL	Not Recruiting			Female: yes Male: yes			Belgium
7	NCT00635141 (ClinicalTrials.gov)	March 2008	4/3/2008	The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis	The Effect of Inhaled Hypertonic Saline (7%) Versus Normal Saline (0.9%) on the Lung Clearance Index in Patients With Cystic Fibrosis	Cystic Fibrosis	Drug: hypertonic saline (7 %) and isotonic saline (0.9%)	The Hospital for Sick Children	Canadian Cystic Fibrosis Foundation	Completed	6 Years	18 Years	Both	20	Phase 3	Canada
8	NCT00506688 (ClinicalTrials.gov)	July 2007	24/7/2007	Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients	Randomized, Placebo-controlled, Double-blinded Study to Investigate the Efficacy and Safety of a 24-week Inhalation Treatment With Glutathione in Cystic Fibrosis Patients	Cystic Fibrosis	Drug: reduced glutathione sodium salt;Drug: 0.9% normal saline (control)	Mukoviszidose Institut gGmbH	Cystic Fibrosis Foundation Therapeutics	Completed	8 Years	N/A	Both	153	Phase 2	Germany
9	EUCTR2007-002707-40-BE (EUCTR)	28/06/2007	04/06/2007	The effect of inhalation with hypertonic saline (7%) on lung function and sputum rheology in Cystic Fibrosis patients	The effect of inhalation with hypertonic saline (7%) on lung function and sputum rheology in Cystic Fibrosis patients	Mucoviscidose MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung	Product Name: Hypertonic saline solution INN or Proposed INN: Sodium Chloride Product Name: Normal saline solution INN or Proposed INN: Sodium Chloride	University Hospital Ghent	NULL	Not Recruiting			Female: yes Male: yes	60		Belgium
10	NCT00671723 (ClinicalTrials.gov)	October 2006	30/4/2008	Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis Patients	Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis	Atelectasis	Drug: Normal saline:;Drug: Hypertonic Saline;Drug: Dornase alpha	University of Oklahoma	NULL	Completed	18 Years	90 Years	All	33	N/A	United States
11	NCT00163852 (ClinicalTrials.gov)	February 2004	12/9/2005	Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis	Salt Replacement for Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis	Cystic Fibrosis	Drug: Normal saline IV, salt tablets	Bayside Health	National Health and Medical Research Council, Australia;Monash University;Cystic Fibrosis Australia	Recruiting	18 Years	75 Years	Both	40	Phase 2/Phase 3	Australia

先頭へ